Literature DB >> 1581908

Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.

F Geissler1, S K Anderson, P Venkatesan, O Press.   

Abstract

The endocytosis and degradation of 125I-labeled anti-mu monoclonal antibody DA4-4 by a Burkitt's lymphoma cell line was investigated using biochemical, chromatographic, electrophoretic, radioautographic, and electron microscopic techniques. 125I-DA4-4 was rapidly internalized by Ramos cells and routed from endosomes to lysosomes. Proteolysis of radiolabeled antibodies began in a late endosomal compartment, but lysosomes were primarily responsible for the terminal degradation of 125I-DA4-4. Catabolism of 125I-DA4-4 could be inhibited by 74-95% by blocking its delivery to late endosomes and lysosomes by incubation at 18 degrees C, by neutralizing the pH in intracellular organelles with monensin or ammonium chloride, or by inhibiting lysosomal enzymes with leupeptin. Radiolabeled antibodies synthesized using the chloramine T or Iodo-Gen techniques were degraded three times faster than conjugates made using a nonmetabolizable 125I-tyramine cellobiose adduct. Five major intermediate metabolites (Mr 48,000, 42,000, 25,000, 15,000, and 10,000) were generated during the intracellular catabolism of 125I-DA4-4, but 125I-tyrosine was responsible for 95% of the small-molecular-weight metabolites released by cells into the culture medium. We anticipate that a full comprehension of the catabolism of radiolabeled antibodies by tumor cells will make possible the development of clinical interventions which will enhance the retention of radioimmunoconjugates by hematologic malignancies and improve the efficacy of radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581908

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

2.  A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.

Authors:  Sai Kiran Sharma; Serge K Lyashchenko; Hijin A Park; Nagavarakishore Pillarsetty; Yorann Roux; Jiong Wu; Sophie Poty; Kathryn M Tully; John T Poirier; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2019-05-03       Impact factor: 2.408

3.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Authors:  Sarah M Cheal; Blesida Punzalan; Michael G Doran; Michael J Evans; Joseph R Osborne; Jason S Lewis; Pat Zanzonico; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

4.  Radioimmunotherapy: no news from the newcomer.

Authors:  A M Mello; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 5.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

6.  Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.

Authors:  Christophe Antczak; Jaspreet S Jaggi; Clare V LeFave; Michael J Curcio; Michael R McDevitt; David A Scheinberg
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

7.  Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Authors:  Tove Olafsen; David Betting; Vania E Kenanova; Felix B Salazar; Pat Clarke; Jonathan Said; Andrew A Raubitschek; John M Timmerman; Anna M Wu
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

Review 8.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

9.  Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging.

Authors:  Vania Kenanova; Bhaswati Barat; Tove Olafsen; Arion Chatziioannou; Harvey R Herschman; Jonathan Braun; Anna M Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-22       Impact factor: 9.236

10.  Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.

Authors:  Zhen Cheng; Lan Zhang; Edward Graves; Zhengming Xiong; Mangal Dandekar; Xiaoyuan Chen; Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.